Oxygen versus ambient air in patients with intermediate-risk acute pulmonary embolism: The AIR randomized clinical trial

David Jimenez, M.D., Ph.D.
Hospital Ramón y Cajal, Universidad de Alcalá, CIBERES
Madrid, Spain

Reversal of hypoxic vasoconstriction is a potential target for treatment in patients with intermediate-risk pulmonary embolism. The AIR investigators aimed within this pilot trial to assess the effect of oxygen in patients with intermediate-risk PE who did not have hypoxemia at baseline using the variant in the two study groups to be supplemental oxygen versus ambient air. RV/LV was studied at a 48-hour interval, showing some efficacy outcomes improved in the supplemental oxygen group.